A
AVIDITY BIOSCIENCES INC
NASDAQ: RNA (Avidity Biosciences, Inc.)
Kemas kini terakhir: 12 jam lalu27.05
-1.36 (-4.79%)
| Penutupan Terdahulu | 28.41 |
| Buka | 28.79 |
| Jumlah Dagangan | 1,626,864 |
| Purata Dagangan (3B) | 1,172,631 |
| Modal Pasaran | 3,227,308,288 |
| Harga / Jualan (P/S) | 372.40 |
| Harga / Buku (P/B) | 3.04 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Operasi (TTM) | -4,200.94% |
| EPS Cair (TTM) | -2.88 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -17.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.51% |
| Nisbah Semasa (MRQ) | 17.76 |
| Aliran Tunai Operasi (OCF TTM) | -184.50 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -135.19 M |
| Pulangan Atas Aset (ROA TTM) | -18.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -27.76% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Avidity Biosciences, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.83% |
| % Dimiliki oleh Institusi | 106.49% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 78.00 (TD Cowen, 188.36%) | Beli |
| Median | 67.00 (147.69%) | |
| Rendah | 60.00 (Needham, 121.81%) | Beli |
| Purata | 68.40 (152.87%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 44.99 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Jan 2025 | 72.00 (166.17%) | Beli | 29.46 |
| 20 Dec 2024 | 72.00 (166.17%) | Beli | 31.82 | |
| RBC Capital | 26 Nov 2024 | 67.00 (147.69%) | Beli | 43.80 |
| Chardan Capital | 13 Nov 2024 | 65.00 (140.30%) | Beli | 52.50 |
| 30 Oct 2024 | 65.00 (140.30%) | Beli | 43.22 | |
| Needham | 13 Nov 2024 | 60.00 (121.81%) | Beli | 52.50 |
| 31 Oct 2024 | 60.00 (121.81%) | Beli | 42.26 | |
| TD Cowen | 21 Oct 2024 | 78.00 (188.35%) | Beli | 46.71 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |